

# Age-related immune response heterogeneity to SARS-C

Nature

596, 417-422

DOI: [10.1038/s41586-021-03739-1](https://doi.org/10.1038/s41586-021-03739-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Will SARS-CoV-2 variants of concern affect the promise of vaccines?. Nature Reviews Immunology, 2021, 21, 340-341.	10.6	162
4	Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes/Metabolism Research and Reviews, 2022, 38, e3465.	1.7	203
5	Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment. Cancers, 2021, 13, 3800.	1.7	27
8	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clinical and Experimental Medicine, 2022, 22, 319-323.	1.9	30
9	Preliminary Structural Data Revealed That the SARS-CoV-2 B.1.617 Variant's RBD Binds to ACE2 Receptor Stronger Than the Wild Type to Enhance the Infectivity. ChemBioChem, 2021, 22, 2641-2649.	1.3	46
10	Aging and CMV Infection Affect Pre-existing SARS-CoV-2-Reactive CD8+ T Cells in Unexposed Individuals. Frontiers in Aging, 2021, 2, .	1.2	16
11	BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects. Life, 2021, 11, 896.	1.1	2
13	Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. EBioMedicine, 2021, 70, 103524.	2.7	53
15	Be Alert to the Risk of Adverse Cardiovascular Events after COVID-19 Vaccination. Exploratory Research and Hypothesis in Medicine, 2021, 000, 000-000.	0.1	0
18	Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ, The, 2021, 374, n2015.	3.0	223
19	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. Cancers, 2021, 13, 4480.	1.7	44
21	Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Regional Health - Europe, The, 2021, 10, 100208.	3.0	446
22	Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. Vaccines, 2021, 9, 1017.	2.1	10
23	The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 2021, 22, 757-773.	7.7	778
28	BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. Frontiers in Immunology, 2021, 12, 743422.	2.2	10
29	SARS-CoV-2-specific T cells in infection and vaccination. Cellular and Molecular Immunology, 2021, 18, 2307-2312.	4.8	131
30	Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-associated Hospitalization among Five Veterans Affairs Medical Centers, United States, February 1-August 6, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1294-1299.	9.0	97
31	Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infectious Diseases, The, 2022, 22, 56-63.	4.6	117

#	ARTICLE	IF	CITATIONS
32	Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine. <i>Vaccines</i> , 2021, 9, 1042.	2.1	64
34	Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e544-e553.	2.0	43
35	COVID-19 mRNA Based Vaccine Immune-Response Assessment for Public Health Decision. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
37	SARS-CoV-2 Infection in Fully Vaccinated Individuals of Old Age Strongly Boosts the Humoral Immune Response. <i>Frontiers in Medicine</i> , 2021, 8, 746644.	1.2	8
38	Barrier Gesture Relaxation during Vaccination Campaign in France: Modelling Impact of Waning Immunity. <i>Covid</i> , 2021, 1, 472-488.	0.7	6
39	Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents. <i>Clinical Microbiology and Infection</i> , 2022, 28, 279-284.	2.8	17
40	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. <i>Life</i> , 2021, 11, 1077.	1.1	25
41	Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 3385.	1.4	3
43	Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment. <i>European Journal of Cancer</i> , 2021, 159, 105-112.	1.3	36
46	A sigh of relief: vaccine-associated hypermetabolic lymphadenopathy following the third COVID-19 vaccine dose is short in duration and uncommonly interferes with the interpretation of [18F]FDG PET-CT studies performed in oncologic patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1338-1344.	3.3	15
47	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
48	Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. <i>Immunity and Ageing</i> , 2021, 18, 38.	1.8	20
49	SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study). <i>American Journal of Transplantation</i> , 2022, 22, 813-822.	2.6	27
50	The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation. <i>Vaccines</i> , 2021, 9, 1209.	2.1	16
52	Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo. <i>Nature Communications</i> , 2021, 12, 6220.	5.8	62
53	Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	44
54	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	5.7	123
55	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42

#	ARTICLE	IF	CITATIONS
56	SARS-CoV-2 mRNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	18
58	BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. <i>Science Immunology</i> , 2021, 6, eabl5344.	5.6	166
59	SARS-CoV-2 Infection in Children Does Not Necessitate Establishment of Adaptive SARS- CoV-2-Specific Immunological Memory. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
60	Mechanisms underpinning poor antibody responses to vaccines in ageing. <i>Immunology Letters</i> , 2022, 241, 1-14.	1.1	28
61	Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. <i>Lancet Rheumatology</i> , The, 2022, 4, e42-e52.	2.2	66
63	Host factors and vaccine efficacy: Implications for COVID-19 vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 1330-1335.	2.5	40
64	Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. <i>Journal of Thoracic Oncology</i> , 2022, 17, 239-251.	0.5	51
65	Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People. <i>Frontiers in Immunology</i> , 2021, 12, 778679.	2.2	54
66	Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients. <i>Cell and Bioscience</i> , 2021, 11, 197.	2.1	32
67	A defective viral genome strategy elicits broad protective immunity against respiratory viruses. <i>Cell</i> , 2021, 184, 6037-6051.e14.	13.5	33
68	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 771242.	2.2	15
69	Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease. <i>Cells</i> , 2021, 10, 3367.	1.8	42
70	Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 273-278.	0.8	19
73	Antibody Response 3 Months after 2 Doses of BNT162b2 mRNA COVID-19 Vaccine in Residents of Long-Term Care Facilities. <i>Gerontology</i> , 2021, , 1-7.	1.4	7
75	Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. <i>Microbiology Spectrum</i> , 2021, 9, e0056121.	1.2	15
76	Current strategies for detecting functional convergence across B-cell receptor repertoires. <i>MAbs</i> , 2021, 13, 1996732.	2.6	18
77	Booster Vaccination Strongly Enhances SARS-CoV-2-Specific Antibody and Cellular Responses in Elderly Residents of Care Homes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	5
78	Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults. <i>Nature Microbiology</i> , 2022, 7, 195-199.	5.9	43

#	ARTICLE	IF	CITATIONS
79	Outcome of SARS-CoV-2 variant breakthrough infection in fully immunized solid organ transplant recipients. <i>Journal of Infection and Public Health</i> , 2022, 15, 51-55.	1.9	7
81	COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. <i>Cancer Cell</i> , 2022, 40, 117-119.	7.7	61
82	COVID-19 outbreak in a long-term care facility in Kelowna, British Columbia after rollout of COVID-19 vaccine in March 2021. <i>Canada Communicable Disease Report</i> , 2021, 47, 543-552.	0.6	2
83	Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2. <i>BMC Medicine</i> , 2022, 20, 32.	2.3	7
84	Axillary Lymphadenopathy on Ultrasound after COVID-19 Vaccination and Its Influencing Factors: A Single-Center Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 238.	1.0	18
85	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. <i>Science</i> , 2022, 375, 183-192.	6.0	91
88	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. <i>Biomedicines</i> , 2022, 10, 204.	1.4	7
89	Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines. <i>Vaccines</i> , 2022, 10, 99.	2.1	13
90	Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases. <i>Viruses</i> , 2022, 14, 207.	1.5	27
91	Hypertension Is Associated With Antibody Response and Breakthrough Infection in Health Care Workers Following Vaccination With Inactivated SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
92	RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine. <i>BMC Infectious Diseases</i> , 2022, 22, 87.	1.3	26
94	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
95	The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program. <i>Vaccines</i> , 2022, 10, 140.	2.1	7
96	Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination. <i>Vaccines</i> , 2022, 10, 114.	2.1	3
97	Modeling the Impact of Vaccination Strategies for Nursing Homes in the Context of Increased Severe Acute Respiratory Syndrome Coronavirus 2 Community Transmission and Variants. <i>Clinical Infectious Diseases</i> , 2022, 75, e880-e883.	2.9	10
99	Effects of <i>Loigolactobacillus coryniformis</i> K8 CECT 5711 on the Immune Response of Elderly Subjects to COVID-19 Vaccination: A Randomized Controlled Trial. <i>Nutrients</i> , 2022, 14, 228.	1.7	18
100	Two Doses of BNT162b2 mRNA Vaccine in Patients after Hematopoietic Stem Cell Transplantation: Humoral Response and Serological Conversion Predictors. <i>Cancers</i> , 2022, 14, 325.	1.7	16
101	mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 821538.	2.2	11

#	ARTICLE	IF	CITATIONS
102	Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study. <i>Vaccines</i> , 2022, 10, 191.	2.1	2
104	B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination. <i>Cell Reports</i> , 2022, 38, 110393.	2.9	29
105	SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. <i>Cell Reports</i> , 2022, 38, 110336.	2.9	41
106	Strategies for fighting pandemic virus infections: Integration of virology and drug delivery. <i>Journal of Controlled Release</i> , 2022, 343, 361-378.	4.8	11
107	Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old. <i>EBioMedicine</i> , 2022, 76, 103852.	2.7	17
109	Humoral and Cellular Responses to COVID-19 Vaccination Indicate the Need for Post-Vaccination Testing in Frail Population. <i>Vaccines</i> , 2022, 10, 260.	2.1	14
110	Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults. <i>Frontiers in Aging</i> , 2022, 3, .	1.2	9
111	Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly. <i>Journal of Immunology</i> , 2022, 208, 1001-1005.	0.4	16
112	Peculiarities of the T Cell Immune Response in COVID-19. <i>Vaccines</i> , 2022, 10, 242.	2.1	24
113	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 342-352.	3.7	100
115	The 90 plus: longevity and COVID-19 survival. <i>Molecular Psychiatry</i> , 2022, , .	4.1	2
116	Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy. <i>JAMA Pediatrics</i> , 2022, 176, 290.	3.3	53
117	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. <i>Cell Reports</i> , 2021, 37, 110143.	2.9	94
118	Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. <i>Lancet Rheumatology</i> , The, 2022, 4, e177-e187.	2.2	122
119	Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. <i>Nature Communications</i> , 2021, 12, 7217.	5.8	80
120	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. <i>Journal of Infectious Diseases</i> , 2022, 225, 1129-1140.	1.9	65
121	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. <i>HemaSphere</i> , 2022, 6, e677.	1.2	17
124	COVID-19 vaccine breakthrough infections. <i>Science</i> , 2021, 374, 1561-1562.	6.0	81

#	ARTICLE	IF	CITATIONS
125	Attenuation of Antibody Titers from 3 to 6 Months after the Second Dose of the BNT162b2 Vaccine Depends on Sex, with Age and Smoking Risk Factors for Lower Antibody Titers at 6 Months. <i>Vaccines</i> , 2021, 9, 1500.	2.1	22
126	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. <i>Science</i> , 2021, , eabm0811.	6.0	10
127	Population antibody responses following COVID-19 vaccination in 212,102 individuals. <i>Nature Communications</i> , 2022, 13, 907.	5.8	94
128	Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizerâ€™BioNTech) in Patients on Hemodialysis. <i>Vaccines</i> , 2022, 10, 327.	2.1	7
129	Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation. <i>Frontiers in Immunology</i> , 2022, 13, 840707.	2.2	11
130	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. <i>Npj Vaccines</i> , 2022, 7, 28.	2.9	64
132	Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System. <i>Vaccines</i> , 2022, 10, 345.	2.1	13
133	Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. <i>Vaccines</i> , 2022, 10, 285.	2.1	13
134	mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2040330.	1.4	5
135	Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old. <i>Frontiers in Immunology</i> , 2022, 13, 812126.	2.2	16
137	Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines. <i>MSphere</i> , 2022, 7, e0091521.	1.3	9
138	Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6.	1.4	20
140	Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 2840-2847.	1.8	10
141	The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. <i>Emerging Microbes and Infections</i> , 2022, 11, 793-803.	3.0	14
142	Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations?. <i>Frontiers in Microbiology</i> , 2022, 13, 763169.	1.5	3
143	Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers. <i>Frontiers in Immunology</i> , 2022, 13, 842912.	2.2	31
145	A comparative impact analysis of different COVID-19 vaccination strategies for older adults across two Canadian provinces. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 1349-1351.	1.3	1
146	Sero-survey on long-term care facility residents reveals increased risk of sub-optimal antibody response to BNT162b2: implications for breakthrough prevention. <i>BMC Geriatrics</i> , 2022, 22, 191.	1.1	7

#	ARTICLE	IF	CITATIONS
148	Sex, Age, and Ethnic Background Shape Adaptive Immune Responses Induced by the SARS-CoV-2 mRNA Vaccine. <i>Frontiers in Immunology</i> , 2022, 13, 786586.	2.2	13
149	Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. <i>Science Translational Medicine</i> , 2022, 14, eabn8057.	5.8	150
150	Matrix stiffness regulates lipid nanoparticle-mRNA delivery in cell-laden hydrogels. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 42, 102550.	1.7	5
151	Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility. <i>Vaccines</i> , 2022, 10, 446.	2.1	7
152	Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCOVER): an interim report from a prospective observational cohort study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e166-e175.	2.0	9
153	Why are children less affected than adults by severe acute respiratory syndrome coronavirus 2 infection?. , 2022, 19, 555-557.		7
154	Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection. <i>Frontiers in Immunology</i> , 2022, 13, 850987.	2.2	35
155	Latent CMV makes older adults less naïve. <i>EBioMedicine</i> , 2022, 77, 103887.	2.7	0
158	B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	5
159	Quantitative restoration of immune defense in old animals determined by naive antigen-specific CD8 T cell numbers. <i>Aging Cell</i> , 2022, 21, e13582.	3.0	6
160	Caring for older adults during the COVID-19 pandemic. <i>Clinical Microbiology and Infection</i> , 2022, 28, 785-791.	2.8	21
162	SARS-CoV-2 variants and vulnerability at the global level. <i>Journal of Medical Virology</i> , 2022, 94, 2986-3005.	2.5	79
163	Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland. <i>Vaccines</i> , 2022, 10, 557.	2.1	15
164	Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 816389.	2.2	5
165	The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1130-1133.	0.9	23
167	Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 52-73.	1.8	11
168	Oxidative stress and endogenous DNA damage in blood mononuclear cells may predict anti-SARS-CoV-2 antibody titers after vaccination in older adults. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166393.	1.8	4
169	Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105156.	1.6	5



#	ARTICLE	IF	CITATIONS
170	COVID-19 mRNA Based Vaccine Immune-Response Assessment in Nursing Home Residents for Public Health Decision. <i>Vaccines</i> , 2021, 9, 1429.	2.1	4
172	Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany. <i>Digestive Diseases</i> , 2022, 40, 719-727.	0.8	14
175	Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population. <i>Vaccines</i> , 2021, 9, 1435.	2.1	8
176	<i>De novo</i> IgA vasculitis following adenovirus-based SARS-CoV-2 vaccination. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 587-589.	1.4	5
177	COVID-19 vaccination strategies depend on the underlying network of social interactions. <i>Scientific Reports</i> , 2021, 11, 24051.	1.6	7
178	What surveys really say. <i>Nature</i> , 2021, 600, 614-615.	13.7	3
179	Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. <i>PLoS Biology</i> , 2021, 19, e3001384.	2.6	15
180	Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2022, 75, e857-e864.	2.9	30
181	Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities. <i>Age and Ageing</i> , 2022, 51, .	0.7	7
182	Differences in Humoral and Cellular Vaccine Responses to SARS-CoV-2 in Kidney and Liver Transplant Recipients. <i>Frontiers in Immunology</i> , 2022, 13, 853682.	2.2	13
183	Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray. <i>Frontiers in Immunology</i> , 2022, 13, 817345.	2.2	5
185	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3020-3031.	0.8	26
186	Predictors of SARS-CoV-2 IgG Spike Antibody Responses on Admission and Clinical Outcomes of COVID-19 Disease in Fully Vaccinated Inpatients: The CoVax Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 640.	1.1	3
188	Comparison of COVID-19 Inactivated Virus Vaccine Immunogenicity Between Healthy Individuals and Patients on Hemodialysis: A Single-Center Study From Pakistan. <i>Cureus</i> , 2022, 14, e24153.	0.2	2
191	Low But Recoverable Markers of Humoral Immune Response to BNT162b2 in Elderly LTCF Residents Five to Seven Months After Two-Dose Vaccination. <i>Frontiers in Aging</i> , 2022, 3, .	1.2	7
192	SARS-CoV-2 Antibody and T Cell Response after a Third Vaccine Dose in Hemodialysis Patients Compared with Healthy Controls. <i>Vaccines</i> , 2022, 10, 694.	2.1	6
193	The Effect of Waning on Antibody Levels and Memory B Cell Recall following SARS-CoV-2 Infection or Vaccination. <i>Vaccines</i> , 2022, 10, 696.	2.1	11
194	Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 649.	2.1	6

#	ARTICLE	IF	CITATIONS
195	The Efficacy of BNT162b2 (Pfizerâ€BioNTech) and CoronaVac Vaccines in Patients with Cancer. <i>Journal of Medical Virology</i> , 2022, , .	2.5	4
196	Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the â€œGreen Passâ€ Policy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
197	Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy. <i>Current Oncology</i> , 2022, 29, 3364-3374.	0.9	5
198	Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. <i>Journal of Infectious Diseases</i> , 2022, 226, 983-994.	1.9	26
199	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
201	Antibody response after two doses of the BNT162b2 vaccine among healthcare workers of a Greek Covid 19 referral hospital: A prospective cohort study. <i>Heliyon</i> , 2022, 8, e09438.	1.4	2
204	Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis. <i>BMJ Open</i> , 2022, 12, e059994.	0.8	17
205	Markers of systemic inflammation are positively associated with influenza vaccine antibody responses with a possible role for ILT2(+)CD57(+) NK-cells. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	6
206	Immune Response 5â€7 Months after Vaccination against SARS-CoV-2 in Elderly Nursing Home Residents in the Czech Republic: Comparison of Three Vaccines. <i>Viruses</i> , 2022, 14, 1086.	1.5	3
207	Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	9
208	Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
210	A cautionary note on altered pace of aging in the COVID-19 era. <i>Forensic Science International: Genetics</i> , 2022, 59, 102724.	1.6	2
211	Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population. <i>Clinical Infectious Diseases</i> , 2023, 76, e391-e399.	2.9	12
212	Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera. <i>Vaccines</i> , 2022, 10, 850.	2.1	5
213	Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination. <i>Nature Communications</i> , 2022, 13, .	5.8	12
214	VOC-alarm: mutation-based prediction of SARS-CoV-2 variants of concern. <i>Bioinformatics</i> , 2022, 38, 3549-3556.	1.8	4
215	Differences in Characteristics of T-Cell Immunity to SARS-CoV-2 in Clinically Healthy Subjects. <i>Bulletin of Experimental Biology and Medicine</i> , 2022, 173, 133-138.	0.3	2
216	B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies. <i>Med</i> , 2022, 3, 468-480.e5.	2.2	2

#	ARTICLE	IF	CITATIONS
217	Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine–Induced Immunity in Older Adults. <i>Clinical Infectious Diseases</i> , 2022, 75, S61-S71.	2.9	27
218	Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2. <i>Vaccine</i> , 2022, 40, 4046-4056.	1.7	24
219	Longitudinal Study of DNA Methylation and Epigenetic Clocks Prior to and Following Test-Confirmed COVID-19 and mRNA Vaccination. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	19
220	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	2.0	1
221	No Differences in Wound Healing and Scar Formation Were Observed in Patients With Different COVID-19 Vaccination Intervals. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	0
224	Limited Cross-Variant Immune Response From SARS-CoV-2 Omicron BA.2 in Naïve But Not Previously Infected Outpatients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
225	Comparison of BNT162b2-, mRNA-1273- and Ad26.COVS.Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants. <i>Vaccines</i> , 2022, 10, 858.	2.1	2
227	Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review. <i>Vaccines</i> , 2022, 10, 909.	2.1	6
228	SARS-CoV-2-specific T <sub>H</sub> cell memory with common TCR $\alpha$ motifs is established in unvaccinated children who seroconvert after infection. <i>Immunity</i> , 2022, 55, 1299-1315.e4.	6.6	23
229	Individuals With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough Infections. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	17
231	SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies. <i>Blood Reviews</i> , 2022, 56, 100984.	2.8	6
232	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	28
233	Risk Factors for Weak Antibody Response of SARS-CoV-2 Vaccine in Adult Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
234	A diminished immune response underlies age-related SARS-CoV-2 pathologies. <i>Cell Reports</i> , 2022, 39, 111002.	2.9	20
236	COVID-19 Vaccines: Update of the vaccines in use and under development. <i>Vacunas</i> , 2022, , .	1.1	6
237	SARS-CoV-2 Seroprevalence, Cumulative Infections, and Immunity to Symptomatic Infection – A Multistage National Household Survey and Modeling Study, Dominican Republic, June–October 2021. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
238	Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
239	The Frequency and Patterns of Post-COVID-19 Vaccination Syndrome Reveal Initially Mild and Potentially Immunocytopenic Signs in Primarily Young Saudi Women. <i>Vaccines</i> , 2022, 10, 1015.	2.1	3

#	ARTICLE	IF	CITATIONS
240	Early human B cell signatures of the primary antibody response to mRNA vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	17
241	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Journal of Clinical Oncology, 2022, 40, 3808-3816.	0.8	19
242	Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals. Journal of Infectious Diseases, 2022, 226, 1407-1411.	1.9	6
243	Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELDâ„¢ or BBV-152 COVAXINâ„¢ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center. Frontiers in Immunology, 0, 13, .	2.2	7
244	A Diagnostic Strategy for Gauging Individual Humoral Ex Vivo Immune Responsiveness Following COVID-19 Vaccination. Vaccines, 2022, 10, 1044.	2.1	3
245	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology, 0, 13, .	2.2	28
247	Landscape of B Cell Receptor Repertoires in COVID-19 Patients Revealed Through CDR3 Sequencing of Immunoglobulin Heavy and Light Chains. Immunological Investigations, 2022, 51, 1994-2008.	1.0	3
248	Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study. The Lancet Healthy Longevity, 2022, 3, e461-e469.	2.0	17
249	Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273. ELife, 0, 11, .	2.8	11
250	Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens. Vaccines, 2022, 10, 1109.	2.1	9
252	Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity. Immunity and Ageing, 2022, 19, .	1.8	6
253	Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Nature Microbiology, 2022, 7, 1180-1188.	5.9	39
254	Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID. EBioMedicine, 2022, 81, 104129.	2.7	21
255	Updated SIOG COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer. Journal of Geriatric Oncology, 2022, , .	0.5	2
256	Differential avidity determination of IgG directed towards the receptorâ€binding domain (RBD) of SARSâ€CoVâ€2 wildtype and its variants in one assay: Rational tool for the assessment of protective immunity.. Journal of Medical Virology, 0, , .	2.5	6
257	Oral antiviral treatments for COVID-19: opportunities and challenges. Pharmacological Reports, 2022, 74, 1255-1278.	1.5	31
258	Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study. EClinicalMedicine, 2022, 51, 101576.	3.2	14
259	Clinical and Virological Features of Patients Hospitalized with Different Types of COVID-19 Vaccination in Mexico City. Vaccines, 2022, 10, 1181.	2.1	2

#	ARTICLE	IF	CITATIONS
260	Contribution of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized Additive Models for Location, Scale, and Shape. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5
261	BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
262	Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in $\beta^2$ -thalassemia: role of an additional dose. <i>Blood</i> , 2022, 140, 1735-1738.	0.6	10
263	Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2. <i>Biomedicines</i> , 2022, 10, 1993.	1.4	8
264	Targeting SARS-CoV-2 papain-like protease in the postvaccine era. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 906-919.	4.0	22
265	Global patterns of antigen receptor repertoire disruption across adaptive immune compartments in COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	10
267	Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study. <i>Life Science Alliance</i> , 2022, 5, e202201479.	1.3	4
268	Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	9
269	B cell intrinsic changes with age do not impact antibody-secreting cell formation but delay B cell participation in the germinal centre reaction. <i>Aging Cell</i> , 2022, 21, .	3.0	10
270	Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	7
271	Immunosenescence, aging and successful aging. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	35
272	Impaired immunity and high attack rates caused by SARS-CoV-2 variants among vaccinated long-term care facility residents. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	3
274	Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
275	mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant. <i>Communications Biology</i> , 2022, 5, .	2.0	15
276	The dark side of Tregs during aging. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
278	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27
280	COVID-19 infection and vaccination in immunodeficiency. <i>Clinical and Experimental Immunology</i> , 2022, 209, 259-261.	1.1	2
281	SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity. <i>Cell Reports</i> , 2022, 40, 111220.	2.9	24

#	ARTICLE	IF	CITATIONS
282	Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged people. <i>JCI Insight</i> , 2022, 7, .	2.3	10
283	Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. <i>BMC Public Health</i> , 2022, 22, .	1.2	15
284	Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
285	Maternal COVID-19 Disease and COVID-19 Immunization. <i>Cureus</i> , 2022, , .	0.2	0
286	The pre-exposure SARS-CoV-2-specific TÂcell repertoire determines the quality of the immune response to vaccination. <i>Immunity</i> , 2022, 55, 1924-1939.e5.	6.6	21
287	SARS-CoV-2 immunity and vaccine strategies in people with HIV. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	12
288	Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 67, 104079.	0.9	12
290	Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines. <i>Microbes and Infection</i> , 2023, 25, 105044.	1.0	7
291	Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
292	Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	7
293	The heterogeneous mixing model of COVID-19 with interventions. <i>Journal of Theoretical Biology</i> , 2022, 553, 111258.	0.8	6
294	SARS CoV-2 IgG Positivity Among the People in Dhaka City: An Observation from the Post Vaccine Period. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
295	T cells in SARS-CoV-2 infection and vaccination. , 2022, 10, 251513552211150.	1.4	4
296	Evaluation of immunoglobulin G level among subjects vaccinated with different types of COVID-19 vaccines in the karbala population, Iraq. <i>Biomedical and Biotechnology Research Journal</i> , 2022, 6, 466.	0.3	4
298	How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9797.	1.8	5
299	Duration of immunity following full vaccination against SARS-CoV-2: a systematic review. <i>Archives of Public Health</i> , 2022, 80, .	1.0	30
300	Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination. <i>IScience</i> , 2022, 25, 105209.	1.9	2
301	Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis. <i>PLoS ONE</i> , 2022, 17, e0273676.	1.1	5

#	ARTICLE	IF	CITATIONS
302	SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria. PLoS ONE, 2022, 17, e0274509.	1.1	8
304	Geriatric Health Care During the COVID-19 Pandemic: Managing the Health Crisis. Clinical Interventions in Aging, 0, Volume 17, 1365-1378.	1.3	10
305	Germany's fourth COVID-19 wave was mainly driven by the unvaccinated. Communications Medicine, 2022, 2, .	1.9	5
307	SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia. BMC Medicine, 2022, 20, .	2.3	18
308	Simulating the efficacy of vaccines on the epidemiological dynamics of SARS-CoV-2 in a membrane computing model. MicroLife, 2022, 3, .	1.0	3
309	SARS-CoV-2 Alpha-Variant Outbreak Amongst a Partially Vaccinated Long-Term Care Facility Population in The Netherlands"Phylogenetic Analysis and Infection Control Observations. Pathogens, 2022, 11, 1070.	1.2	0
310	Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population. Journal of Infection, 2022, 85, 702-769.	1.7	6
311	Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort. Vaccines, 2022, 10, 1542.	2.1	9
312	SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study. Scientific Reports, 2022, 12, .	1.6	17
313	Coronavirus Vaccination: Spike Antibody Levels in Health Workers after Six Months" A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 11422.	1.2	1
314	SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study. Viruses, 2022, 14, 1966.	1.5	6
315	Vaccination Decreases the Infectious Viral Load of Delta Variant SARS-CoV-2 in Asymptomatic Patients. Viruses, 2022, 14, 2071.	1.5	8
316	The bullwhip effect, T-cell telomeres, and SARS-CoV-2. The Lancet Healthy Longevity, 2022, 3, e715-e721.	2.0	2
317	BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. Cell Reports, 2022, 41, 111544.	2.9	17
318	Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. Med, 2022, 3, 838-847.e3.	2.2	26
319	How aging impacts vaccine efficacy: known molecular and cellular mechanisms and future directions. Trends in Molecular Medicine, 2022, 28, 1100-1111.	3.5	13
320	Memory T cell responses in seronegative older adults following SARS-CoV-2 vaccination. Clinical Immunology Communications, 2022, 2, 154-158.	0.5	1
321	Parallel detection of SARS-CoV-2 epitopes reveals dynamic immunodominance profiles of CD8 <sup>+</sup> T memory cells in convalescent COVID-19 donors. Clinical and Translational Immunology, 2022, 11, .	1.7	10

#	ARTICLE	IF	CITATIONS
322	Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
323	Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review. <i>British Journal of Cancer</i> , 2022, 127, 1827-1836.	2.9	18
324	Emerging cellular senescence-centric understanding of immunological aging and its potential modulation through dietary bioactive components. <i>Biogerontology</i> , 2022, 23, 699-729.	2.0	8
325	Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. <i>Nature Medicine</i> , 2023, 29, 147-157.	15.2	32
326	Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003979.	3.9	24
327	Broad Antiviral Effects of <i>Echinacea purpurea</i> against SARS-CoV-2 Variants of Concern and Potential Mechanism of Action. <i>Microorganisms</i> , 2022, 10, 2145.	1.6	3
328	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
330	Antibody and T-Cell Subsets Analysis Unveils an Immune Profile Heterogeneity Mediating Long-term Responses in Individuals Vaccinated Against SARS-CoV-2. <i>Journal of Infectious Diseases</i> , 2023, 227, 353-363.	1.9	2
331	A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network. <i>Trials</i> , 2022, 23, .	0.7	2
332	Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	4
333	SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa. <i>Nature Communications</i> , 2022, 13, .	5.8	14
334	Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults. <i>Nature Aging</i> , 2022, 2, 896-905.	5.3	20
335	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
336	Longitudinal Analyses after COVID-19 Recovery or Prolonged Infection Reveal Unique Immunological Signatures after Repeated Vaccinations. <i>Vaccines</i> , 2022, 10, 1815.	2.1	0
339	COVID-19 breakthrough infections in vaccinated participants of the Safety and Efficacy of Preventative COVID Vaccines sub-study. <i>Jammi</i> , 0, , .	0.3	0
340	Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients. <i>iScience</i> , 2022, 25, 105369.	1.9	7
342	Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC). <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642211353.	1.5	6
343	Gender and age features of the formation of a humoral immune response to COVID-19 vaccination. <i>Laboratornaya Sluzhba</i> , 2022, 11, 17.	0.0	0



#	ARTICLE	IF	CITATIONS
344	Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113977.	2.5	66
345	Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19. <i>Infectious Diseases and Therapy</i> , 2023, 12, 177-191.	1.8	2
347	Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
348	Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
349	Do we need to vaccinate every child against COVID-19: What evidence suggestsâ€”A systematic review of opinions. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	9
350	Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
351	Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities. <i>Npj Vaccines</i> , 2022, 7, .	2.9	10
352	SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection â€” A multistage national household survey and modelling study, Dominican Republic, Juneâ€”October 2021. <i>The Lancet Regional Health Americas</i> , 2022, 16, 100390.	1.5	2
353	Correlation between Clinical and Immunological Variables and Humoral Response to SARS-CoV-2 Vaccination in Adult Patients with Antibody Deficiency Disorders. <i>Pathogens</i> , 2022, 11, 1364.	1.2	1
354	Absence of antibody responses to SARS-CoV-2 N protein in COVID-19 vaccine breakthrough cases. <i>Experimental Biology and Medicine</i> , 2022, 247, 1923-1936.	1.1	1
355	Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the Coronavirus National Vaccine registry for Immune diseases SINGapore (CONVIN-SING). <i>Journal of Autoimmunity</i> , 2023, 134, 102959.	3.0	9
356	Ad26.COVS.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. <i>IScience</i> , 2023, 26, 105753.	1.9	4
357	SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses. <i>AIMS Microbiology</i> , 2022, 8, 422-453.	1.0	1
358	COVID-19 vaccines: Update of the vaccines in use and under development. <i>Vacunas (English Edition)</i> , 2022, 23, S88-S102.	0.3	0
359	A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19. <i>Vaccines</i> , 2022, 10, 2043.	2.1	0
360	SARS-CoV-2 Specific Humoral Immune Responses after BNT162b2 Vaccination in Hospital Healthcare Workers. <i>Vaccines</i> , 2022, 10, 2038.	2.1	2
361	Enhanced Vaccine Effectiveness during the Delta Phase of the COVID-19 Pandemic in the Medicare Population Supports a Multilayered Prevention Approach. <i>Biology</i> , 2022, 11, 1700.	1.3	1
362	Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. <i>PLoS Medicine</i> , 2022, 19, e1004037.	3.9	28

#	ARTICLE	IF	CITATIONS
364	Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign. <i>European Journal of General Practice</i> , 2023, 29, .	0.9	2
365	Longitudinal age differences in humoral responses to the COVID-19 vaccine in the elderly are lost after the third dose. <i>Journal of Infection</i> , 2022, , .	1.7	4
367	COVID-19 Era and the Constantly Reemerging Novel SARS-CoV-2 Variants Calls for Special Attention for the Geriatrics: A Real Challenge. <i>Geriatrics (Switzerland)</i> , 2022, 7, 143.	0.6	3
369	T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents. <i>Journal of the American Medical Directors Association</i> , 2023, 24, 140-147.e2.	1.2	6
371	Vaccine-associated corneal graft rejection following SARS-CoV-2 vaccination: a CDC-VAERS database analysis. <i>British Journal of Ophthalmology</i> , 2024, 108, 17-22.	2.1	4
372	Durability of humoral and cell-mediated immune response after SARS-CoV-2 mRNA vaccine administration. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	5
373	Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations. <i>Vaccine: X</i> , 2022, 12, 100246.	0.9	3
374	Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older. <i>Vaccine</i> , 2023, 41, 914-921.	1.7	3
375	Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	18
376	Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8+ T cell immunity in CLL and MDS patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
377	COVID-19 vaccines and a perspective on Africa. <i>Trends in Immunology</i> , 2023, 44, 172-187.	2.9	4
378	Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients. <i>Microorganisms</i> , 2023, 11, 191.	1.6	3
379	The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. <i>Virology Journal</i> , 2023, 20, .	1.4	41
380	Impaired CD4+ T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination. <i>Nature Aging</i> , 2023, 3, 82-92.	5.3	23
381	SARS-CoV-2 mRNA Dual Immunization Induces Innate Transcriptional Signatures, Establishes T-Cell Memory and Coordinates the Recall Response. <i>Vaccines</i> , 2023, 11, 103.	2.1	1
382	The risk of adverse cardiovascular complications following covid-19 vaccination. <i>Pharmacy &amp; Pharmacology International Journal</i> , 2023, 11, 10-13.	0.1	0
383	COVID-19 Vaccinesâ€”All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
384	An inactivated recombinant rabies virus chimerically expressed RBD induces humoral and cellular immunity against SARS-CoV-2 and RABV. <i>Virologica Sinica</i> , 2023, 38, 244-256.	1.2	3

#	ARTICLE	IF	CITATIONS
385	Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians. <i>PLoS ONE</i> , 2023, 18, e0280276.	1.1	2
386	Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes. <i>Nature Aging</i> , 2023, 3, 93-104.	5.3	10
388	Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
389	Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants. <i>Bioengineering</i> , 2023, 10, 148.	1.6	3
390	Humoral signatures of MOG-antibody-associated disease track with age and disease activity. <i>Cell Reports Medicine</i> , 2023, 4, 100913.	3.3	7
391	SARS-CoV-2 infection and immune responses. <i>AIMS Microbiology</i> , 2023, 9, 245-276.	1.0	2
392	SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients. <i>Transplant International</i> , 0, 36, .	0.8	1
393	Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: A real-life study. <i>Revista Espanola De Geriatria Y Gerontologia</i> , 2023, 58, 125-133.	0.2	4
394	Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines. <i>Viruses</i> , 2023, 15, 917.	1.5	1
395	Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy. <i>Vaccines</i> , 2023, 11, 806.	2.1	1
396	Antibody response dynamics to CoronaVac vaccine and booster immunization in adults and the elderly: a long-term, longitudinal prospective study. <i>IJID Regions</i> , 2023, , .	0.5	0
398	Impact of proactive and reactive vaccination strategies for health-care workers against MERS-CoV: a mathematical modelling study. <i>The Lancet Global Health</i> , 2023, 11, e759-e769.	2.9	2
400	Age and Cytokine Gene Variants Modulate the Immunogenicity and Protective Effect of SARS-CoV-2 mRNA-Based Vaccination. <i>Vaccines</i> , 2023, 11, 413.	2.1	1
401	The Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination and Infection on Neutralizing Antibodies: A Nation-wide Cross-sectional Analysis. <i>Journal of Infectious Diseases</i> , 2023, 227, 1255-1265.	1.9	4
402	Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
403	Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis. <i>Vaccine</i> , 2023, 41, 1791-1798.	1.7	6
404	Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, .	1.3	5
405	The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups. <i>Pathogens</i> , 2023, 12, 329.	1.2	3

#	ARTICLE	IF	CITATIONS
406	Factors Influencing Antibody Response to SARS-CoV-2 Vaccination. <i>Vaccines</i> , 2023, 11, 451.	2.1	4
407	A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. <i>Cell Reports Medicine</i> , 2023, 4, 100971.	3.3	4
408	Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals. <i>Communications Biology</i> , 2023, 6, .	2.0	17
410	Practical Guide to Honest Causal Forests for Identifying Heterogeneous Treatment Effects. <i>American Journal of Epidemiology</i> , 2023, 192, 1155-1165.	1.6	9
411	Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination. <i>EBioMedicine</i> , 2023, 89, 104475.	2.7	4
413	Higher plasma levels of thymosin- $\alpha$ 1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home. <i>Immunity and Ageing</i> , 2023, 20, .	1.8	1
414	SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	9
415	Adenosine deaminase augments SARS-CoV-2 specific cellular and humoral responses in aged mouse models of immunization and challenge. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
416	SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: An ISARIC4C prospective study. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
417	Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia. <i>Blood Advances</i> , 0, , .	2.5	1
418	Temporal pattern of humoral immune response in mild cases of COVID-19. <i>World Journal of Biological Chemistry</i> , 0, 14, 40-51.	1.7	0
419	<sc>ChAdOx1 nCoV</sc> $\alpha$ 19 vaccination generates spike-specific <sc>CD8</sc> <sup>+</sup> T cells in aged mice. <i>Immunology and Cell Biology</i> , 0, , .	1.0	0
420	COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series. <i>IScience</i> , 2023, 26, 106506.	1.9	4
421	Complexity of the Immune Response Elicited by Different COVID-19 Vaccines, in the Light of Natural Autoantibodies and Immunomodulatory Therapies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6439.	1.8	4
422	Understanding the COVID-19 Vaccine Policy Terrain in Ontario Canada: A Policy Analysis of the Actors, Content, Processes, and Context. <i>Vaccines</i> , 2023, 11, 782.	2.1	2
423	Limited induction of polyfunctional lung-resident memory T cells against SARS-CoV-2 by mRNA vaccination compared to infection. <i>Nature Communications</i> , 2023, 14, .	5.8	8
424	The impact of frailty syndrome on humoral response to SARS-CoV-2 mRNA vaccines in older kidney transplant recipients. <i>International Urology and Nephrology</i> , 0, , .	0.6	0
425	Human immune and gut microbial parameters associated with inter-individual variations in COVID-19 mRNA vaccine-induced immunity. <i>Communications Biology</i> , 2023, 6, .	2.0	8

#	ARTICLE	IF	CITATIONS
467	Immunogenicity of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV; Sinopharm) and Short-Term Clinical Outcomes in Vaccinated Solid Organ Transplant Recipients: A Prospective Cohort Study. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 357-374.	0.8	0
510	SARS-CoV-2 and innate immunity: the good, the bad, and the "goldilocks", 2024, 21, 171-183.		4
512	BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer. <i>Npj Vaccines</i> , 2023, 8, .	2.9	0
524	Microfluidic-assisted single-cell RNA sequencing facilitates the development of neutralizing monoclonal antibodies against SARS-CoV-2. <i>Lab on A Chip</i> , 2024, 24, 642-657.	3.1	0